Home | Links | Contact Us | More About Intellectual Property | Bookmark
Search patents:
Home Drugs Nucleic-acids-encoding-lymphoid-CD30-antigen

 CTLA4/CD28Ig hybrid fusion proteins and uses thereof
OF THE INVENTION DEFINITION As used in this application, the following words or phrases have the ...


 Method of regulating cellular processes mediated by B7 and CD28
Accordingly, the present invention identifies the B7 antigen as a ligand recognized by the CD28 ...


 Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
This invention is based, at least in part, on the discovery of novel ligands which bind a T cell ...


 Method for generating and identifying antibodies directed against a B7
Accordingly, the present invention identifies the B7 antigen as a ligand recognized by the CD28 ...


 Polypeptide that interacts with heat shock proteins
Described herein are the isolation and characterization of a polypeptide, particularly a ...


 1,2-Biguanides
What is claimed is: 1. A substituted biguanide of the formula ##EQU8## wherein R.sub.1 is alkyl of 1...


 Biguanide salts
OF THE INVENTION The invention relates to biguanide salts. In another aspect, the invention ...


 Inhibitors of dipeptidyl-aminopeptidase type IV
What is claimed is: 1. A method for treating transplant rejection in a patient comprising ...


 Process for preparing anti-obesity protein
OF THE INVENTION For purposes of the present invention, as disclosed and claimed herein, the ...


 Use of GLP-1 or analogs to abolish catabolic changes after surgery
The present invention therefore presents for the first time a method of attenuating post-surgical ...


 Nucleic acids encoding lymphoid CD30 antigen

Details
Inventors: Stein, Harald; Durkop, Horst; Latza, Ute;
Assignee:
Primary Examiner: Spector; Lorraine
Assistant Examiner:
Attorney, Agent or Firm: Birch, Stewart, Kolasch & Birch, LLP

The description relates to the lymphoid surface antigen CD30 (Ki-1) occurring in Hodgkin's disease, the protein sequence and the associated nucleotide sequence therein, manufacture thereof by genetic engineering, methods for diagnosis and investigation of Hodgkin's disease and use of these nucleotide sequences for producing transgenic animals. The invention provides methods not based on monoclonal antibodies for investigation and diagnosis of anaplastic large-cell lymphomas.

DETAILED DESCRIPTION We claim: 1.
An isolated nucleic acid molecule comprising a polynucleotide having a sequence encoding the amino acid sequence of SEQ.
ID.
NO.
: 2.
2.
A recombinant vector comprising an isolated nucleic acid of claim 1.
3.
A cell transformed with a recombinant vector of claim 2.
4.
An isolated nucleic acid molecule comprising a polynucleotide having the nucleotide sequence of SEQ.
ID.
NO.
1.
5.
A recombinant vector comprising an isolated nucleic acid of claim 4.
6.
A cell transformed with a recombinant vector of claim 5.
7.
A method for producing a CD30 protein comprising: i) culturing a transformed cell of claim 3 or 6; and ii) recovering CD30 protein produced by the cultured host cell.
8.
A method for preparing a hybridization probe comprising: i) isolating a restriction fragment of the DNA molecule of claim 1 or claim 4 and its complementary strand; ii) nick-translating the restriction fragment of step (i) in the presence of a labeled nucleotide to obtain a labeled hybridization probe.
9.
A hybridization probe prepared according to the method of claim 8.
10.
An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence selected from the group consisting of a sequence encoding the portion of the amino acid sequence of SEQ.
ID.
NO.
2 from residue 19 to residue 379; a sequence encoding the portion of the amino acid sequence of SEQ.
ID.
NO.
2 from residue 408 to residue 595; a sequence encoding the portion of the amino acid sequence of SEQ.
ID.
NO.
2 from residue 19 to residue 93; a sequence encoding the portion of the amino acid sequence of SEQ.
ID.
NO.
2 from residue 112 to residue 416; the sequence from nucleotide 218 to nucleotide 1732 of SEQ.
ID.
NO.
1; the sequence from nucleotide 277 to nucleotide 1359 of SEQ.
ID.
NO.
1; and the sequence from nucleotide 1444 to nucleotide 2007 of SEQ.
ID.
NO.
1.
11.
A recombinant vector comprising an isolated nucleic acid of claim 10.
12.
A cell transformed with a recombinant vector of claim 11.
13.
A hybridization probe comprising the nucleic acid of claim 1 or 10 and a label selected from the group consisting of radioactive atoms, stain groups, or epitopes introduced for systems based on light or enzymatic stain reactions for detection of nucleic acids



Related patents
  Feeding tray for multiwell test apparatus
This invention will be described herein with reference to the growing and use of cells on a membrane positioned and secured to the bottom of each of a multiplicity of ...
  Neo-tryptophan
What is claimed is: 1. A method of making a neurotensin polypeptide containing neo-tryptophan, said method comprising: a) providing a neo-tryptophan derivative, and b) ...
  Human immunodeficiency virus decoy
OF THE INVENTION The present invention has wide application to immunologic procedures and methods wherein antigenic material or other biologically active moieties are ...
  Capsid forming and cystein modified chimaeric MS2-coat protein
We claim: 1. A modified coat protein capable of forming a capsid which comprises the coat protein of a bacteriophage selected from the group consisting of MS-2, R17 and ...
  Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
This invention relates to the discovery of an anti-idiotype antibody that is capable of recruiting a tumor-specific response against GD2. The antibody is designated 1A7....
  Strategically modified hepatitis B core proteins and their derivatives
The present invention relates to a strategically modified hepatitis B core (HBc) protein that is linked to a pendent hapten through chemically-reactive amino acid ...
  Chimeric biotin-binding papillomavirus protein
OF THE INVENTION The first domain of the chimeric protein includes at least a portion of a papillomavirus L1 or L2 protein. The sequence of the L1 and L2 proteins of ...
  Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
OF THE INVENTION DEFINITIONS As used in this application, the following words or phrases have the meanings specified. As used herein, a "bispecific fusion protein" ...
  MYPPPY variants of CTL A4 and uses thereof
OF THE INVENTION Definition As used in this application, the following words or phrases have the meanings specified. As used herein "blocking B7 interaction" means to ...
  CTLA4 receptor and uses thereof
OF THE INVENTION DEFINITION As used in this application, the following words or phrases have the meanings specified. As used herein "blocking B7 interaction" means to ...

0.004

Archive: All patents - Links

Copyright (c)2006 Eipa-patents.org - All rights reserved